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Abstract
Background:  While hearing loss in HIV-infected people after beginning nucleoside reverse
transcriptase inhibitors (NRTIs) has been reported, there have been no prospective studies that
measured hearing changes longitudinally in treatment-naïve HIV-infected subjects following
initiation of regimens containing NRTIs. The goal of this study was to conduct a prospective
assessment of the contribution of zidovudine (ZDV) and didanosine (ddI) to hearing loss
Methods/design: A prospective observational pilot study to determine whether ZDV or ddI,
alone or in combination, are associated with sensorineural hearing loss in HIV-infected persons.
Changes in hearing levels at all frequencies and in low and high frequency pure tone averages were
measured at baseline, 16, and 32 weeks after initiating antiretroviral therapy.
Discussion: Treatment with ZDV and ddI did not result in loss of hearing, even after taking into
account noise exposure, immune status and age. The results of this prospective pilot study do not
support the notion that treatment with nucleoside antiretrovirals damages hearing.
Background
Cross-sectional studies and case reports show that hearing
loss may be common among HIV-infected people [1-3].
Hearing loss may be associated with HIV infection itself,
opportunistic infections, or ototoxic drug therapy [1].
However, in up to 50% of HIV-infected people with hear-
ing loss, no cause can be identified [4]. In a prior cross sec-
tional study, we showed that hearing loss was common in
HIV-infected people and was associated with older age
and antiretroviral use, but we were unable to determine
an association with specific antiretroviral agents [1].
While hearing loss in HIV-infected people after beginning
nucleoside reverse transcriptase inhibitors (NRTIs) has
been reported [5], there have been no prospective studies
that measured hearing changes longitudinally in treat-
ment-naïve HIV-infected subjects following initiation of
regimens containing NRTIs. The goal of this study was to
conduct a prospective assessment of the contribution of
zidovudine (ZDV) and didanosine (ddI) to hearing loss.
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Methods/design
Study design
Thirty three antiretroviral-naïve subjects with their most
recent peripheral blood CD4+ T-cells > 200/ul performed
within the past 3 months were prospectively enrolled in
this study between January 1996 and December 1999.
Subjects were recruited from one research and one outpa-
tient medical clinic for persons with HIV-1. (An AIDS
Clinical Trials Unit and a public, hospital-based, HIV pri-
mary care clinic staffed by university faculty and ID fel-
lows.) All subjects initiated therapy with regimens
containing either ZDV or ddI, and although use of only
one of these agents was preferred, use of both was
allowed. People with prior hearing loss requiring hearing
aids, and those with active substance abuse that would
interfere with their participation in the trial were
excluded. All subjects signed an Institutional Review
Board-approved consent prior to participation in this
study.
Subjects underwent audiometry prior to initiating antiret-
roviral therapy (entry) and at weeks 16 and 32. At each
visit, plasma HIV RNA and CD4+ T-cells were measured.
Audiometry
All audiometric testing was completed by a certified audi-
ologist or under their direct supervision. Following oto-
scopic inspection, tympanometry screening was
performed to rule out significant middle ear pathology.
Audiometric testing was completed with the use of a clin-
ical diagnostic audiometer (Grason Stadler, Model GSI
61) in a sound-treated test booth. Air conduction thresh-
olds were obtained for each ear at 250, 500, 1000, 2000,
3000, 4000, 6000, 8000 and 12000 hertz (Hz). Pure tone
bone conduction testing was administered on those per-
sons demonstrating hearing loss by air conduction. Hear-
ing levels were measured at 250, 500, 1000, 2000, 3000,
4000, 6000, 8000 and 12000 Hz by formal audiometry.
"Hearing Level" was defined as the intensity of the sound
(in dB – decibels) needed to reach threshold (both for air
conduction and bone conduction). Normal hearing is
generally considered to be 0–25 dB hearing level [6]. Pure
tone hearing sensitivity was tested using air conduction
(with earphones, which tests the entire auditory system),
and then by bone conduction (using an oscillator behind
the ear, which bypasses the outer and middle ear). The
comparison of air conduction thresholds and bone con-
duction thresholds can differentiate a sensorineural hear-
ing loss versus a conductive hearing loss.
HIV-1 RNA assays
Plasma HIV-1 RNA was measured using the Roche Ultra-
Sensitive PCR Amplicor HIV-1 Monitor test (Roche
Molecular Diagnostics, Branchburg, New Jersey). Values
below the limit of detection (50 c/ml) were imputed to be
25. All viral loads were log10 transformed for analysis.
Data analysis
Due to the lack of a standard definition of ototoxicity, we
evaluated changes in hearing using several methods [7].
Associations between categorical and continuous varia-
bles were assessed by Chi-square or t-tests. The association
between baseline hearing level and baseline health meas-
ures was examined using linear regression with jackknifed
robust standard errors to protect estimation against viola-
tion of the equivariance assumption [8]. Hearing levels at
16 and 32 weeks were analyzed as the change from base-
line using generalized estimating equations (GEE) with an
Table 1: Patient demographic characteristics at entry. (P-values are from t-tests comparing those who took each drug to those who 
did not.)
All Subjects Subjects with follow up Exposed to ZDV* Exposed to ddI†
N 3 32 31 97
Age in years: Mean (Range) 35.3 (23 – 51) 35.5 (23 – 51) 36.2 (23 – 51) (p = .27) 35.4 (25 – 51) (p = .97)
Male, N (%) 31 (94%) 21 (91%) 18 (95%) (p = .20) 6 (86%) (p = .53)
Race, N (%)
White
Black
Hispanic
Asian
24 (73%)
3 (9%)
1 (3%)
5 (15%)
16(70%)
2 (9%)
1 (4%)
4 (17%)
14 (74%)
1 (5%)
0 (0%)
4 (21%) (p = .062)
6 (86%)
0 (0%)
1 (14%)
0 (0%) (p = .15)
CD4+ T-cells/ul Mean 
(Range)
483 (213 – 1130) 481 (213 – 960) 472 (213 – 960) (p = .64) 714 (444 – 960) (p < .0001)
Plasma HIV RNA‡ 1000 
copies per/ml Mean 
(Range)
102 (0.1 – 670) (N = 31) 75 (0.1 – 505) (N = 22) 87 (0.1 – 505) (p = .69) 2.8 (0.1 – 8.0) (p = .0006)
Low Frequency PTA§in dB 
Mean (Range)
11 (0 – 40) (N = 32) 12 (0 – 40) 14 (1 – 40) (p = .41) 16 (0.5 – 40) (p = .40)
High Frequency PTA in dB 
Mean (Range)
20 (0.8 – 51) (N = 32) 22 (1.7 – 51) 22 (2 – 51) (p = .98) 23 (3 – 50) (p = .64)
*ZDV = zidovudine, †ddI = didanosine, ‡RNA = ribonucleic acid, §PTA = pure tone averageBMC Infectious Diseases 2006, 6:28 http://www.biomedcentral.com/1471-2334/6/28
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exchangeable working correlation matrix, an identity link
function and Gaussian error distribution. The GEE
approach was chosen to allow use of data from both visits
while appropriately accounting for the correlation
between the 16 week and 32 week measurements of the
same patient [9]. In the GEE models, patients were classi-
fied as on ZDV (or ddI) if they had taken it at any prior
time in the study. Two patients began ZDV, and one
patient began ddI, between 16 and 32 weeks. All three
were classified in the no drug group at 16 weeks and the
drug group at 32 weeks. Hearing level in the left and right
ears was averaged to generate a single value at each fre-
quency for each individual. In addition to the individual
frequencies, a low frequency pure tone average (PTA) was
computed as the mean in both ears at 500, 1000 and 2000
Hz and a high frequency PTA was computed as the mean
in both ears at 4000, 8000 and 12000 Hz. Missing indi-
vidual frequency hearing levels occurred in 11 subjects at
one of the three observations and these values were
imputed for the purposes of the analysis. These values
were calculated based on the average of the adjacent
higher and lower frequency hearing level measured at that
visit. P values of ≤ 0.05 were considered significant, and
the median age of 35 years was chosen to dichotomize age
in the analysis of age effects.
Discussion
Findings at the entry visit
The demographics of the 33 subjects included in the anal-
ysis, shown in Table 1, were representative of the epi-
demic in the local area at the time this study was accrued:
primarily gay, white men. Subjects were well balanced
with regard to baseline hearing in the ZDV versus ddI
exposure group in terms of their demographic characteris-
tics. However, the subjects who began taking ddI were
healthier at study entry than those who initiated therapy
with ZDV, with lower plasma HIV RNA levels and signifi-
cantly higher CD4+ T-cell counts.
At study entry, 22 of 33 subjects had a hearing level greater
than 25 dB at one or more frequencies in one or both ears,
16 had at least one hearing level greater than 40 dB and 7
had at least one hearing level greater than 60 dB. Most of
the decreased hearing sensitivity was at higher frequen-
cies. No one had a hearing level above 40 dB in both ears
at 2000 Hz or lower, whereas 9 subjects had a hearing
level above 40 dB in both ears at 12000 Hz, 2 subjects had
a hearing level above 40 dB in both ears at 6000 and 8000
Hz, and 3 subjects had a hearing level above 40 dB in both
ears at 3000 and 4000 Hz. Only 4 subjects reported a his-
tory of occupational sound exposure, and 12 subjects
reported a history of recreational sound exposure. Tinni-
tus was reported at entry in 14/33 (42%) subjects.
Low and high frequency PTA at baseline were not signifi-
cantly associated with baseline viral load or baseline
CD4+ T-cell count. (Table 2)
Two subjects had a history of an AIDS-defining illness
(one subject with previous Pneumocystis jiroveci pneumo-
nia and one with previous esophageal candidiasis). Their
mean low frequency PTA was the same as the subjects
without an AIDS diagnosis (11 dB). The mean high fre-
quency PTA for subjects with an AIDS diagnosis (28 dB)
was higher than subjects without an AIDS diagnosis (20
dB), but the difference was not significant (p = 0.40).
Findings at follow-up visits
Twenty-two of the 33 subjects returned at 16 weeks and
nineteen returned at 32 weeks. Four patients had a 16-
week visit and no 32-week visit and one patient had a 32-
week visit and no 16-week visit. Subjects with follow up
had a trend toward worse hearing at baseline, compared
to baseline hearing in subjects who did not follow up, but
these differences were not significant. Specifically, the
baseline low frequency PTA in those with follow-up was
5.1 dB higher than in those without follow-up (p = .19)
and the baseline high frequency PTA in those with follow-
up was 6.5 dB higher than in those without follow-up (p
= .22). The difference in baseline high and low frequency
PTAs between those with and without a 16-week visit is
similar to the difference between those with and without
a 32-week visit, and both are similar to the difference
between those with any follow up and those with no fol-
Table 2: Mean difference in hearing level (HL) at baseline and mean change in hearing level associated with variation in baseline 
plasma HIV RNA and baseline CD4+ T-cell count.*
Baseline Plasma HIV RNA
(Population difference in dB per 10-fold increase)
Baseline CD4+ T-cell count
(Population difference in dB per 100 cells/mL increase)
Baseline HL Change in HL† Baseline HL Change in HL†
Low Frequency PTA‡ -2.3 (-7.9 – 3.2) p = 0.395 -0.016 (-0.93 – 0.90) p = 0.333 0.50 (-1.7 – 2.7) p = 0.646 - 0.27 (-0.86 – 0.31) p = 0.354
High Frequency PTA -0.44 (-7.9 – 7.0) p = 0.906 0.34 (-1.7 – 2.4) p = 0.747 -0.29 (-2.7 – 2.2) p = 0.801 0.089 (-0.71 – 0.53) p = 0.780
*A negative value indicates improved hearing and a positive value indicates worse hearing
†Adjusted for baseline pure tone average and time since baseline.
‡PTA = Pure Tone AverageBMC Infectious Diseases 2006, 6:28 http://www.biomedcentral.com/1471-2334/6/28
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low up. Those with follow up had lower plasma HIV RNA
concentration at entry (0.74 log10 copies/ml lower, p =
0.046), but peripheral blood CD4+ T-cell count at entry
did not differ between the two groups (p = 0.94).
Although patients with higher CD4+ T-cell counts at entry
had greater improvement in low frequency PTA, this dif-
ference did not reach statistical significance (Table 2).
Table 3 shows the change in hearing level for each fre-
quency at each time point for subjects in both treatment
groups combined. Overall, there was a trend towards
improvement, but it did not reach clinical (20 dB or more
at 1 frequency) nor statistical significance.
Table 4 shows estimates and 95% confidence intervals for
the change in PTA associated with taking ZDV and ddI
from GEE models adjusting for week, baseline PTA and
age. There were no significant changes in hearing over the
32 weeks of observation in subjects taking ZDV or ddI,
even taking into account age.
We also used GEE models to examine the dose-response
relationship of either ZDV or ddI together by adding
together the number of days each patient took each drug;
thus, a patient who was taking both drugs for 60 days had
120 drug-days of exposure and a patient taking ZDV but
not ddI for 30 days who then switched to ddI for 30 days
would have 60 drug-days of exposure. Longer treatment
with ZDV and ddI did not influence change in pure tone
averages.
Influence of noise exposure and tinnitus
At baseline, the low and high frequency PTAs for those
with a history of occupational or recreational noise expo-
sure did not differ from those without such exposure (data
not shown). Similarly, the change in PTAs did not differ
between the two groups (data not shown). While there
was a trend to decreased tinnitus reported at week 16, (7/
21, 33%) and week 32 (3/19, 16%), compared to 42% at
baseline, these changes did not reach statistical signifi-
cance. (p = .49 at 16 weeks, and p = .053 at 32 weeks).
Table 3: Mean and standard deviation of hearing level in dB for each frequency at baseline and mean and standard deviation of change 
in hearing level (average of R & L ear).
Frequency (Hz) Baseline – All subjects (dB) Baseline – Subjects with 
follow up (dB)
Change at 16 wks* (dB) Change at 32 wks* (dB)
Number of subjects 33 23 22 19
250 13.3 +/- 8.0 14.8 +/- 8.3 -1.6 +/- 5.1 -2.1 +/- 5.1
500 11.3 +/- 8.6 12.7 +/- 9.8 -0.6 +/- 5.1 -2.1 +/- 5.1
1000 11.2 +/- 9.8 11.4 +/- 11.3 -0.6 +/- 3.2 0.0 +/- 3.0
2000 9.6 +/- 12.0 11.3 +/- 13.1 -0.5 +/- 3.9 0.0 +/- 2.8
3000 13.6 +/- 13.7 16.1 +/- 14.8 -0.3 +/- 4.5 0.0 +/- 2.8
4000 17.4 +/- 14.9 19.1 +/- 15.8 -0.9 +/- 4.5 -1.1 +/- 5.7
6000 20.5 +/- 13.7 22.6 +/- 14.7 0.6 +/- 5.6 -0.2 +/- 6.9
8000 23.4 +/- 14.5 25.0 +/- 15.0 -2.2 +/- 5.6 -0.4 +/- 7.2
12000 36.3 +/- 19.7 37.9 +/- 19.1 -0.6 +/- 8.4 0.0 +/- 11.4
Low Freq PTA 11.5 +/- 9.8 12.1 +/- 10.8 -0.6 +/- 2.5 -0.9 +/- 2.0
High Freq PTA 20.4 +/- 13.4 22.2 +/- 14.2 -0.8 +/- 4.8 -0.6 +/- 5.2
*A negative value indicates improved hearing and a positive value indicates worse hearing
Table 4: Mean difference in, and 95% confidence interval for, change from baseline hearing level in dB for patients receiving regimens 
containing ZDV or ddI, estimated by GEE model adjusting for time since beginning therapy, baseline hearing level, and age.*
Low Frequency PTA† High Frequency PTA
All patients Age < 35 years Age ≥ 35 years All patients Age < 35 years Age ≥ 35 years
ZDV 4.0 (-1.4 – 9.5) 3.9 (-0.6 – 8.4) 4.5 (-2.1 – 11.0)
p = 0.70
1.2 (-1.2 – 3.5) 1.5 (-1.7 – 4.8) 0.80 (-2.4 – 4.0)
p = 0.75
ddI - 2.6 (-6.1 – 0.9)
p = 0.91
- 0.6 (-2.5 – 1.2) - 5.4 (-13.8 – 3.1)
p = 0.31
0.2 (-3.1 – 2.7) - 0.2 (-3.3 – 2.8) - 0.1 (-3.7 – 3.5)
p = 0.95
Combined
(per 100 drug-days) ‡
- 0.08 (-1.2 – 1.0)
p = 0.89
-0.28 (-0.80 – 1.4)
p = 0.61
-0.45 (-1.6 – 0.69)
p = 0.44
-0.047 (-1.4 – 1.3)
p = 0.75
0.098 (-2.0 – 1.3)
p = 0.92
-0.22 (-1.6 – 1.2)
p = 0.70
*A positive value indicates worsening hearing level; a negative value indicates improved hearing level.
†Pure Tone Average
‡Cumulative total number of days each patient took ZDV and ddIBMC Infectious Diseases 2006, 6:28 http://www.biomedcentral.com/1471-2334/6/28
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We conducted this longitudinal study to evaluate changes
in hearing following the initiation of therapy with ZDV,
ddI, or both drugs in antiretroviral therapy (ART)-naïve
subjects. There were no significant changes in hearing at
16 and 32 weeks, even taking into account noise exposure,
CD4+ T-cell count and plasma viral load. Our previous
cross-sectional study, which was larger (99 versus 24 sub-
jects), showed an interaction between antiretroviral use
and age [1]. Limitations of our present study include small
sample size, lack of randomization to ZDV or ddI, dura-
tion of follow up, and lack of a control group. The
strength of our study is the use of detailed audiometry
before and after beginning NRTIs in treatment-naïve sub-
jects.
Prior cross-sectional studies and case reports have shown
an association between hearing loss and NRTI therapy [1-
3]. The results of the current prospective study do not con-
firm this relationship and are consistent with the report
from the Adult/Adolescent Spectrum of HIV Disease
Project Group that demonstrated no association between
hearing loss and age. Of note, however, that study was
based on a retrospective chart review for ICD-9 coding for
hearing loss and not on formal audiometry [3].
There have been two case reports of hearing loss in sub-
jects receiving ART regimens that included NRTIs and a
second class of antiretrovirals; one with a non-nucleoside
reverse transcriptase inhibitor (NNRTI) (nevirapine) and
one with a protease inhibitor (PI) (lopinavir/ritonavir)
each combined with NRTIs, (both these subjects were also
receiving stavudine and lamivudine). One case reported
sudden hearing loss two weeks after the person completed
one month of post-exposure prophylaxis which resulted
in long-term hearing loss [10]. The other case reported
hearing loss in a subject with extensive HIV pretreatment,
and suggested a possible relationship with the protease
inhibitor, although the were other possible explanations
noted in Simdon's reply to this case report [11,12]. Sim-
don reported three subjects who experienced ototoxicity,
all of whom were over the age of 45 and received combi-
nation ART with 2–3 NRTIs plus a NNRTI or a PI. All 3 of
the subjects had prior hearing problems, prior exposure to
occupational noise and all developed significant tinnitus
[2]. The authors suggested that NRTIs should be used
sparingly in patients with preexisting hearing loss. While
our study excluded subjects with prior hearing loss requir-
ing hearing aids and included younger participants, sev-
eral subjects had baseline hearing loss yet we saw no
deterioration in hearing after beginning NRTIs. Also, we
observed a trend towards less tinnitus over the 32 weeks
of nucleoside therapy.
Our finding of little impact on hearing after beginning
ZDV or ddI is reassuring and suggests that, if such agents
do cause hearing loss, it is uncommon. Alternatively,
baseline hearing impairment due to HIV itself may
improve with improved immune status as a result of
antiretroviral treatment, masking any potential ototoxic-
ity. This hypothesis could be tested in a future study by
comparing hearing changes in subjects who do and do not
experience improved immune status after beginning
NRTIs.
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